OBJECTIVE: We sought to determine the frequency, risk factors, and impact on functional outcome and quality of life (QOL) of global cognitive impairment 1 year after subarachnoid hemorrhage. METHODS: We prospectively evaluated global cognitive status 3 and 12 months after hospitalization with the Telephone Interview for Cognitive Status in 232 subarachnoid hemorrhage survivors. Cognitive impairment was defined as a score of 30 or less (scaled 0 = worst, 51 = best). Logistic regression was performed to calculate adjusted odds ratios (AORs) for impairment at 1 year. Basic activities of daily living were evaluated with the Barthel Index, instrumental activities of daily living were assessed with the Lawton scale, and QOL was evaluated with the Sickness Impact Profile. RESULTS: The frequency of cognitive impairment was 27% at 3 months and 21% at 12 months. After the effects of age, education, and race/ethnicity were controlled for, risk factors for cognitive impairment at 12 months included anemia treated with transfusion (AOR, 3.4; P = 0.006), any temperature level higher than 38.6 degrees C (AOR, 2.7; P = 0.016), and delayed cerebral ischemia (AOR, 3.6; P = 0.01). Among cognitively impaired patients at 3 months, improvement at 1 year occurred in 34% and was associated with more than 12 years of education and the absence of fever higher than 38.6 degrees C during hospitalization (P = 0.015). Patients with cognitive impairment at 1 year had worse concurrent QOL and less ability to perform instrumental and basic activities of daily living (all P < 0.001). CONCLUSION: Global cognitive impairment affects more than 20% of subarachnoid hemorrhage survivors at 1 year, is predicted by fever, anemia treated with transfusion, and delayed cerebral ischemia, and adversely affects functional recovery and QOL.
OBJECTIVE: We sought to determine the frequency, risk factors, and impact on functional outcome and quality of life (QOL) of global cognitive impairment 1 year after subarachnoid hemorrhage. METHODS: We prospectively evaluated global cognitive status 3 and 12 months after hospitalization with the Telephone Interview for Cognitive Status in 232 subarachnoid hemorrhage survivors. Cognitive impairment was defined as a score of 30 or less (scaled 0 = worst, 51 = best). Logistic regression was performed to calculate adjusted odds ratios (AORs) for impairment at 1 year. Basic activities of daily living were evaluated with the Barthel Index, instrumental activities of daily living were assessed with the Lawton scale, and QOL was evaluated with the Sickness Impact Profile. RESULTS: The frequency of cognitive impairment was 27% at 3 months and 21% at 12 months. After the effects of age, education, and race/ethnicity were controlled for, risk factors for cognitive impairment at 12 months included anemia treated with transfusion (AOR, 3.4; P = 0.006), any temperature level higher than 38.6 degrees C (AOR, 2.7; P = 0.016), and delayed cerebral ischemia (AOR, 3.6; P = 0.01). Among cognitively impairedpatients at 3 months, improvement at 1 year occurred in 34% and was associated with more than 12 years of education and the absence of fever higher than 38.6 degrees C during hospitalization (P = 0.015). Patients with cognitive impairment at 1 year had worse concurrent QOL and less ability to perform instrumental and basic activities of daily living (all P < 0.001). CONCLUSION: Global cognitive impairment affects more than 20% of subarachnoid hemorrhage survivors at 1 year, is predicted by fever, anemia treated with transfusion, and delayed cerebral ischemia, and adversely affects functional recovery and QOL.
Authors: J Ivanidze; R A Charalel; I Shuryak; D Brenner; A Pandya; O N Kallas; K Kesavabhotla; A Z Segal; M S Simon; P C Sanelli Journal: AJNR Am J Neuroradiol Date: 2017-01-12 Impact factor: 3.825
Authors: Gabriela A Santos; Nils Petersen; Amir A Zamani; Rose Du; Sarah LaRose; Andrew Monk; Farzaneh A Sorond; Can Ozan Tan Journal: Neurology Date: 2016-04-22 Impact factor: 9.910
Authors: H Baradaran; V Fodera; D Mir; K Kesavabhotla; K Kesavobhotla; J Ivanidze; U Ozbek; A Gupta; J Claassen; P C Sanelli Journal: AJNR Am J Neuroradiol Date: 2015-05-14 Impact factor: 3.825
Authors: Christopher L Kramer; Marianna Pegoli; Jay Mandrekar; Giuseppe Lanzino; Alejandro A Rabinstein Journal: Neurocrit Care Date: 2017-02 Impact factor: 3.210
Authors: Pedro Kurtz; J Michael Schmidt; Jan Claassen; Emmanuel Carrera; Luis Fernandez; Raimund Helbok; Mary Presciutti; R Morgan Stuart; E Sander Connolly; Neeraj Badjatia; Stephan A Mayer; Kiwon Lee Journal: Neurocrit Care Date: 2010-08 Impact factor: 3.210
Authors: P C Sanelli; A Pandya; A Z Segal; A Gupta; S Hurtado-Rua; J Ivanidze; K Kesavabhotla; D Mir; A I Mushlin; M G M Hunink Journal: AJNR Am J Neuroradiol Date: 2014-05-08 Impact factor: 3.825
Authors: Khalil M Yousef; Jeffrey R Balzer; Elizabeth A Crago; Samuel M Poloyac; Paula R Sherwood Journal: Intensive Crit Care Nurs Date: 2014-06-02 Impact factor: 3.072